The mechanism of two new drugs for treating basal cell carcinoma

In an article published in the journal Cell, the leading scientists from the United States transformed Genomics Research Institute (TGen) and the Mayo Clinic detailedly describe the mechanism of two relatively new drug helping patients with basal cell carcinoma.

Basal cell carcinoma is the most common type of skin cancer in the United States with nearly 2.8 million new cases in each year. The sunny Arizona has the world's highest incidence of skin cancer. Anti-cancer drugs and Sonidegib Vismodegib inhibit a component of Hedgehog cell signaling pathway - a protein called the Smoothened (SMO). According to this article published in the journal Cell on February 25th, unchecked SUMO sends a signal to other proteins along the Hedgehog signaling pathway, resulting in the activation of cancer.

The journal Cell specially invited Dr. Daniel Von Hoff and Aleksandar Sekulic made the report. Dr. Von Hoff is a famous professor and chief physician in transforming Genomics Institute. He is also the chief scientist in clinical trials cooperated by HonorHealth and TGen and Clinical medicine Professor of Mayo. Dr. Aleksandar Sekulic is an associate professor of dermatology and deputy director of the Department of Dermatology as well as deputy director of the Mayo Clinic Personalized Medicine Medical Center.

In the latter an FDA Phase I clinical trial led by TGen and Mayo Clinic-led Phase II clinical trial, in 2012, approved Vismodegib as a first line treatment of basal cell carcinoma. This is at TGen-HonorHealth cooperation test; get the first drug approved by the FDA, and the FDA-approved treatment inoperable basal cell carcinoma of the first drug.

In 2009, "New England Journal of Medicine" (NEJM) Journal, Dr. Von Hoff recorded some initial findings described Vismodegib effects in dealing with some of the Hedgehog signaling pathway gene mutation.

Dr. Sekulic led to the subsequent stage Mayo Clinic Vismodegib pivotal clinical trials, so that in 2012 Vismodegib received FDA approval. Published in 2012 in the second article in NEJM, Sekulic study has found Vismodegib (trade name Erivedge) in 43% of patients with locally advanced basal cell carcinoma and 30% of patients with metastasis in patients with reduced basal cell carcinoma tumors.

It received FDA approval in 2015 of a second SUO inhibitor Sonidegib (trade name Odomzo) in patients with locally advanced basal cell carcinoma in the response rate was 44%. It is not approved for treatment of metastatic cancers.

Basal cell carcinoma (BCC) is the most common form of cancer, 90% of people there is risk, especially in older people, UV radiation and more. Although this cancer is common, it is not very deadly. So far, the understanding of the BCC is still very limited. To this end, the University of Geneva (UNIGE) of geneticists sequenced these skin tumors DNA, which identified the oncogene. The study published in the March 2016 Nature Genetics magazine for new personalized therapy foundation.

SMO inhibitors have in clinical studies for the treatment of various cancers. Although the majority of patients receive Vismodegib after treatment, access to significant clinical benefits, but some patients often develop resistance. Published in the journal Cancer Cell 2015, two papers discussed basal cell carcinoma drug resistance mechanisms.

Basal cell carcinoma is the most common cancer in the population of European. Although it is not as fatal as other skin cancers, it can be disfiguring. Researchers reported in 2009 in the journal Nature Genetics that they had identified two new variations associated with basal cell carcinoma.

More details: http://www.cusabio.com/Clone/CT0239-1089564.html